BRIEF-ImmunityBio Initiates Review After Receiving FDA Letter On ANKTIVA Promotional Materials

Reuters03-24

March 24 (Reuters) - Immunitybio Inc IBRX.O:

IMMUNITYBIO- ACKNOWLEDGES RECEIPT OF OPDP LETTER DATED MARCH 13, REGARDING SOME PROMOTIONAL MATERIALS FOR ANKTIVAÒ (NOGAPENDEKIN ALFA INBAKICEPT-PMLN)
IMMUNITYBIO- TAKE FDA’S CONCERNS SERIOUSLY AND HAVE INITIATED A REVIEW OF LETTER WITH LEGAL AND REGULATORY TEAMS
IMMUNITYBIO: INTEND TO RESPOND TO FDA WITHIN REQUESTED TIMEFRAME AND WORK COOPERATIVELY WITH AGENCY TO ADDRESS MATTERS RAISED IN LETTER

Further company coverage: IBRX.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621771096?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 23:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621771096","market":"us","top_or_hot":-1,"title":"BRIEF-ImmunityBio Initiates Review After Receiving FDA Letter On ANKTIVA Promotional Materials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-ImmunityBio Initiates Review After Receiving FDA Letter On ANKTIVA Promotional Materials</title></head><body><p><span>March 24 (Reuters)</span><span> - </span>Immunitybio Inc <span>IBRX.O</span>:</p><ul><li><p>IMMUNITYBIO- ACKNOWLEDGES RECEIPT OF OPDP LETTER DATED MARCH 13, REGARDING SOME PROMOTIONAL MATERIALS FOR ANKTIVAÒ (NOGAPENDEKIN ALFA INBAKICEPT-PMLN)</p></li><li><p>IMMUNITYBIO- TAKE FDA’S CONCERNS SERIOUSLY AND HAVE INITIATED A REVIEW OF LETTER WITH LEGAL AND REGULATORY TEAMS</p></li><li><p>IMMUNITYBIO: INTEND TO RESPOND TO FDA WITHIN REQUESTED TIMEFRAME AND WORK COOPERATIVELY WITH AGENCY TO ADDRESS MATTERS RAISED IN LETTER</p></li></ul><p>Further company coverage: <span>IBRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-ImmunityBio Initiates Review After Receiving FDA Letter On ANKTIVA Promotional Materials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-ImmunityBio Initiates Review After Receiving FDA Letter On ANKTIVA Promotional Materials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-24 23:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-ImmunityBio Initiates Review After Receiving FDA Letter On ANKTIVA Promotional Materials</title></head><body><p><span>March 24 (Reuters)</span><span> - </span>Immunitybio Inc <span>IBRX.O</span>:</p><ul><li><p>IMMUNITYBIO- ACKNOWLEDGES RECEIPT OF OPDP LETTER DATED MARCH 13, REGARDING SOME PROMOTIONAL MATERIALS FOR ANKTIVAÒ (NOGAPENDEKIN ALFA INBAKICEPT-PMLN)</p></li><li><p>IMMUNITYBIO- TAKE FDA’S CONCERNS SERIOUSLY AND HAVE INITIATED A REVIEW OF LETTER WITH LEGAL AND REGULATORY TEAMS</p></li><li><p>IMMUNITYBIO: INTEND TO RESPOND TO FDA WITHIN REQUESTED TIMEFRAME AND WORK COOPERATIVELY WITH AGENCY TO ADDRESS MATTERS RAISED IN LETTER</p></li></ul><p>Further company coverage: <span>IBRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0B2:1","article_id":"2621771096","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621771096","pubTimestamp":1774366097,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-ImmunityBio Initiates Review After Receiving FDA Letter On ANKTIVA Promotional MaterialsMarch 24  - Immunitybio Inc IBRX.O:IMMUNITYBIO- ACKNOWLEDGES RECEIPT OF OPDP LETTER DATED MARCH 13, REGARDING SOME PROMOTIONAL MATERIALS FOR ANKTIVA IMMUNITYBIO- TAKE FDA’S CONCERNS SERIOUSLY AND HAVE INITIATED A REVIEW OF LETTER WITH LEGAL AND REGULATORY TEAMSIMMUNITYBIO: INTEND TO RESPOND TO FDA WITHIN REQUESTED TIMEFRAME AND WORK COOPERATIVELY WITH AGENCY TO ADDRESS MATTERS RAISED IN LETTERFurther company coverage: IBRX.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc.","BK4139":"生物科技"},"translate_title":"简介-ImmunityBio在收到FDA关于ANKTIVA宣传材料的信函后启动审查","themeId":"7e2294d99a26f40e351ca07cad557479","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"BRIEF-ImmunityBio Initiates Review After Receiving FDA Letter On ANKTIVA Promotional MaterialsMarch 24 (Reuters) - Immunitybio Inc IBRX.O:IMMUNITYBIO- ACKNOWLEDGES RECEIPT OF OPDP LETTER DATED MARCH 13, REGARDING SOME PROMOTIONAL MATERIALS FOR ANKTIVAÒ (NOGAPENDEKIN ALFA INBAKICEPT-PMLN)IMMUNITYBIO- TAKE FDA’S CONCERNS SERIOUSLY AND HAVE INITIATED A REVIEW OF LETTER WITH LEGAL AND REGULATORY TEAMSIMMUNITYBIO: INTEND TO RESPOND TO FDA WITHIN REQUESTED TIMEFRAME AND WORK COOPERATIVELY WITH AGENCY TO ADDRESS MATTERS RAISED IN LETTERFurther company coverage: IBRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621771096","isCrawlerRequest":true}